Antipsychotic Drugs Market Size, Share and Trends Analysis, By Drug, By Therapeutic Class (First Generation, Second Generation, and Third Generation), By Route of Administration (Oral, Parenteral, and Injected, By Indication, By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and By Region, Forecast 2025-2032

Antipsychotic Drugs Market Overview and Key Insights:

The antipsychotic drugs market size reached USD 18.86 billion in 2024 and is expected to register a revenue CAGR of 7.6% during the forecast period. Neuroleptics, or antipsychotic drugs, are used to treat and manage symptoms associated with various psychiatric diseases.

Market Drivers:

Rising prevalence of mental health disorders and aging population is a key driver of revenue growth in the antipsychotic drugs market. According to the National Institute of Mental Health, in 2022, there were a predicted 59.3 million adults aged 18 and up in the United States with Any Mental Illness (AMI). The prevalence of AMI was highest among young adults aged 18-25 years (36.2%), followed by individuals aged 26-49 years (29.4%) and 50 and older (13.9%). AMI was most prevalent among adults reporting two or more races (35.2%), followed by White adults (24.6%). The frequency of AMI was lowest among Asian people (16.8%).

Furthermore, according to the Anxiety and Depression Association of America, anxiety disorder is the most prevalent mental illness in the U.S., affecting 40 million individuals aged 18 or older, or 18.1% of the population, every year. Anxiety disorders are found in nearly half of people diagnosed with depression. Generalized Anxiety Disorder (GAD) affects 6.8 million adults or 3.1% of the U.S. population, yet only 43.2% are receiving treatment.

On September 2024, Bristol Myers Squibb stated that the United States Food and Drug Administration (FDA) has approved COBENFY (xanomeline and trospium chloride), an oral medicine for the treatment of schizophrenia in adults. COBENFY combines xanomeline, a dual M 1 – and M 4 -preferring muscarinic receptor agonist, with trospium chloride, a muscarinic receptor antagonist that does not pass the blood-brain barrier and acts largely on peripheral tissues.

Market Opportunity:

Integration of digital health and Artificial Intelligence (AI) acts as an opportunity for the antipsychotic drugs market. Integrating AI provides a great opportunity for transformative innovation in mental health care. AI is propelling the creation of individualized, efficient mental health solutions. Both established corporations and startups are pioneering novel ways based on individual biochemistry and patient preferences.

Predictive models can also warn physicians and patients to potential relapse risks, allowing for prompt interventions and modifications to treatment strategies. AI-driven drug repurposing efforts have the potential to speed up the development of new medicines for mental health illnesses by discovering current pharmaceuticals that may have previously undiscovered therapeutic properties.

On September 2023, PsychoGenics Inc. and Collaborations Pharmaceuticals, Inc. announced that they have received a USD 1 million Phase I Small Business Innovation Research (SBIR) grant to leverage their integrated AI capabilities to develop novel medications for mental health diseases. The firms will create and use machine learning (ML) methods to investigate new areas of chemistry, with the goal of discovering medicines that address unique or numerous elements of complicated neuropsychiatric illnesses.

Recent Trends:

Emerging trends include Long-Acting Injectable (LAI) antipsychotics, AI-driven drug discovery, personalized and precision psychiatry, and nanotechnology in drug delivery.

One of the most important uses of AI in medicinal chemistry is predicting the efficacy and toxicity of new therapeutic molecules. Another major application of AI in drug development is detecting drug-drug interactions, which occur when multiple medications are combined for the same or different conditions in the same patient, resulting in changed effects or bad reactions. This problem can be identified using AI-based techniques that analyze vast datasets of known medication interactions and recognize patterns and trends.

On October 2024, Recursion, a leading TechBio firm that decodes biology to fundamentally enhance people’s lives, and Google Cloud announced an expanded relationship that will use Google Cloud’s technologies to assist Recursion’s drug development platform. This strategic relationship will investigate generative AI capabilities, such as Gemini models, to enable the RecursionOS, improve search and access with BigQuery, and scale computational resources.

Restraints & Challenges:

Although newer antipsychotic medicines are safer and less likely to cause movement-related side effects, many still have long-term concerns, including weight gain, diabetes, metabolic disorders, and cardiovascular disease. Second-generation antipsychotics are labeled with an FDA warning about an elevated risk of stroke in senior dementia patients.

Clozapine may produce hypersalivation, tachycardia, hypotension, and anticholinergic adverse effects. It is remarkable in that it inhibits dyskinesia and can produce clinically significant agranulocytosis and leukopenia, necessitating monitoring of white blood cell and absolute neutrophil counts.

Therapeutic Class Segment Insights and Analysis:

Based on the therapeutic class, the antipsychotic drugs market is segmented into first generation, second generation, and third generation.

Second generation segment contributed the largest market share in 2024. Second-generation antipsychotics are serotonin-dopamine antagonists, commonly referred to as atypical antipsychotics. Extrapyramidal symptoms, the most common side effect of FGAs, are less likely to occur with second generation antipsychotics. They have also been used as an adjuvant treatment for disruptive behavior disorders with aggression that have failed to respond to stimulant therapy.

On March 2025, Neurocrine Biosciences, Inc. has announced the start of a Phase 1 clinical research to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of investigational chemical NBI-1140675 in healthy adult subjects. NBI-1140675 is an oral, selective second-generation small molecule inhibitor of the vesicular monoamine transporter 2 (VMAT2) that is being developed for the treatment of certain neurological and neuropsychiatric diseases. NBI-1140675, like NBI-1065890, is a second-generation VMAT2 inhibitor being evaluated by Neurocrine in Phase 1 clinical trials.

Drug Segment Insights and Analysis:

Based on the drug, the antipsychotic drugs market is segmented into Risperidone, Quetiapine, Olanzapine, Aripiprazole, Brexpiprazole, Paliperidone Palmitate, and Others.

Aripiprazole segment contributed the largest market share in 2024. The FDA has approved aripiprazole, an atypical antipsychotic. Clinicians primarily use it to manage psychosis symptoms in patients with schizophrenia and to treat acute manic episodes in bipolar disorder, either alone or in combination with other therapies. They also prescribe aripiprazole as an add-on treatment for major depression and Tourette syndrome. Studies have shown that aripiprazole reduces psychiatric hospitalization rates, alleviates symptoms of tardive dyskinesia, improves cognitive function, and lowers cardiovascular risk factors, plasma lipid concentrations, and prolactin levels.

On April 2023, Otsuka America Pharmaceutical, Inc. and Lundbeck have announced that the US Food and Drug Administration has approved the New Drug Application (NDA) for ABILIFY ASIMTUFII (aripiprazole) extended-release injectable suspension for intramuscular use, a once-every-two-months injection for the treatment of schizophrenia in adults, or for maintenance monotherapy treatment of bipolar I disorder in adults. ABILIFY ASIMTUFII, a long-acting injectable, delivers medication continuously and can sustain therapeutic plasma concentrations, potentially benefiting those with schizophrenia and bipolar I disorder.

Indication Segment Insights and Analysis:

Based on the indication, the antipsychotic drugs market is segmented into in schizophrenia, bipolar disorder, major depressive disorder, dementia-related psychosis, tourette syndrome, Autism Spectrum Disorders (ASD), and others.

Schizophrenia segment contributed the largest market share in 2024. According to the World Health Organization (WHO), schizophrenia affects about 24 million people, or one in every 300 persons (0.32%) worldwide. This rate is 1 in 222 persons (0.45%) among adults (2). It is less prevalent than many other mental diseases. Onset occurs most frequently in late adolescence and the twenties, and males tend to experience it earlier than women. Women develop schizophrenia later than men, and the clinical signs are less severe. This could be due to the antidopaminergic effects of estrogen.

On April 2025, Luye Pharma Group has announced that ERZOFRI (paliperidone palmitate) extended-release injectable solution and available for commercial sale in the United States for the treatment of adults with schizophrenia and as a monotherapy or adjunct therapy for adults with schizoaffective disorder. ERZOFRI, which is given once a month, distributes the active component, paliperidone, via a long-acting, extended-release delivery mechanism. It streamlines therapy by allowing for single-dose initiation thanks to its unique 351 mg initiation dose.

Geographical Outlook:

Antipsychotic drugs market is strategically segmented by geography to provide a comprehensive understanding of regional market dynamic. Discover demand analysis, emerging trends, and growth opportunities shaping market performance across different region and countries.

North America Antipsychotic Drugs Market:

North America is registered to have largest market share in antipsychotic drugs market in 2024. This is mainly due to the rising prevalence of mental health disorders and aging population and surging R&D initiatives for the development of novel antipsychotics. According to the Alzheimer’s Association, Alzheimer’s disease affects more than 7 million Americans. By 2050, this figure is expected to increase to approximately 13 million. Health and long-term care costs for people with dementia are expected to reach USD 384 billion in 2025 and nearly USD 1 trillion in 2050. Nearly 12 million Americans offer unpaid care to persons suffering from Alzheimer’s disease or other forms of dementia. Nearly three-fifths of Americans answered they would accept moderate or extremely high levels of risk in exchange for slowing the advancement of Alzheimer’s disease.

On January 2025, Eisai Co., Ltd. and Biogen Inc. announced that the US Food and Drug Administration (FDA) has approved the Supplemental Biologics License Application for lecanemab-irmb intravenous (IV) maintenance dose every four weeks. LEQEMBI is approved for the treatment of Alzheimer’s disease (AD) in patients with mild cognitive impairment (MCI) or mild dementia in the United States.

Asia Pacific Antipsychotic Drugs Market:

Asia Pacific is registered the fastest growth rate during the forecasted period. The region is boosted by increasing focus of governments and health care organizations on mental health. India has achieved significant progress in mental healthcare through policy reforms, technology efforts like Tele MANAS, and increased access to services through programs like NMHP, Ayushman Bharat HWCs, and the National Suicide Prevention Strategy. The Ministry of Health and Family Welfare (MoHFW) launched the National Suicide Prevention Strategy (NSPS) in 2022, aiming to reduce suicide mortality by 10% by 2030. The plan addresses suicide as a public health risk, emphasizing early intervention, crisis management, and mental health promotion.

On January 2025, Bajaj Healthcare reported that it has received approval from the medication Controller General of India (DCGI) to manufacture a medication to treat Parkinson’s disease-related hallucinations and delusions. The company has gained approval to manufacture both the API and the medication formulation of Pimavanserin, a 34 mg capsule. It is an atypical antipsychotic used to treat hallucinations and delusions caused by Parkinson’s disease psychosis.

Competition Analysis:

The antipsychotic drugs market is characterized by a fragmented structure, with several players competing across various segments and regions. List of major players included in the antipsychotic drugs market report are:

• AbbVie Inc
• Roche
• Sumitomo Pharma Co., Ltd.
• Teva Pharmaceutical Industries Ltd.
• Bristol-Myers Squibb Company
• Reddy’s Laboratories Ltd.
• Johnson & Johnson, Inc
• Otsuka Pharmaceutical Co., Ltd.
• Mylan N.V.
• Amneal Pharmaceuticals LLC
• Novartis AG
• GSK plc.
• Boehringer Ingelheim International GmbH
• Sun Pharmaceutical Industries Ltd.
• Pfizer Inc.
• Lundbeck A/S

Strategic Developments in Antipsychotic Drugs Market:

• In May 2025, Sunshine Biopharma Inc., a pharmaceutical company that offers and researches life-saving medicines in a variety of therapeutic areas such as oncology and antivirals, announced that its wholly owned Canadian subsidiary, Nora Pharma Inc., has launched Lurasidone, a new generic prescription drug in the antipsychotic therapeutic class. Lurasidone is a generic form of Latuda. Lurasidone is recommended for the treatment of schizophrenia and bipolar disorder.
• In February 2025, Teva Pharmaceuticals, a US affiliate of Teva Pharmaceutical Industries Ltd., and Medincell announced that the FDA has accepted the supplemental New Drug Application (sNDA) for UZEDY extended-release injectable suspension for the maintenance treatment of bipolar disorder-1 (BP-I) in adults. The sNDA is based on UZEDY’s existing clinical data, as well as the Agency’s previous findings on the safety and efficacy of risperidone formulations approved for the treatment of BP-I.
• In March 2024, Boehringer Ingelheim and Sosei Group Corporation announced that they have signed an exclusive option-to-license agreement and embarked into a global collaboration. The shared goal of the center is to create and market Sosei Heptares’ first-in-class GPR52 agonists, a novel G protein-coupled receptor (GPCR) target, to enhance patient outcomes by concurrently treating positive, negative, and cognitive symptoms of schizophrenia.

Key Advantages for Stakeholders:

Navistrat Analytics’ industry report provides an in-depth quantitative analysis of various market segments, historical and current trends, market forecasts, and dynamics within the global market. The historical years covered in this report are 2022 to 2023, with 2024 serving as the base year for market size calculations. The forecast period extends from 2025 to 2032.

The report includes an executive summary and a comprehensive overview of market drivers, restraints, opportunities, and challenges (DROC), along with insights into regulatory standards. It features detailed analyses such as PORTER’s Five Forces, SWOT, and PESTLE, as well as assessments of technological trends and the competitive landscape.

PORTER’s Five Forces analysis helps stakeholders evaluate the impact of new entrants, competitive rivalry, supplier power, buyer power, and substitution threats, enabling them to assess the level of competition and the attractiveness of the global market. The competitive landscape provides stakeholders with a clear understanding of the current market positions of key players, offering valuable insights into their competitive environment.

Scope And Key Highlights of the Antipsychotic Drugs Market Report:

The Antipsychotic Drugs market report offers a detailed analysis of market size, including historical revenue (in USD Billion) data for 2022-2023 and revenue forecasts for 2025-2032 across the following segments:

• Drug Outlook (Revenue, USD Billion; 2022-2032)
  • Risperidone
  • Quetiapine
  • Olanzapine
  • Aripiprazole
  • Brexpiprazole
  • Paliperidone Palmitate
  • Others

• Therapeutic Class Outlook (Revenue, USD Billion; 2022-2032)
  • First Generation
  • Second Generation
  • Third Generation

• Route of Administration Outlook (Revenue, USD Billion; 2022-2032)
  • Oral
  • Parenteral
  • Injected

• Indication Outlook (Revenue, USD Billion; 2022-2032)
  • Schizophrenia
  • Bipolar Disorder
  • Major Depressive Disorder
  • Dementia-related Psychosis
  • Tourette Syndrome
  • Autism Spectrum Disorders (ASD)
  • Others

• Indication Outlook (Revenue, USD Billion; 2022-2032)
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

• Regional Outlook (Revenue, USD Billion; 2022-2032)
  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • U.K.
    • Italy
    • Spain
    • Benelux
    • Nordic Countries
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • South Korea
    • Oceania
    • ASEAN Countries
    • Rest of APAC
  • Latin America
    • Brazil
    • Rest of LATAM
  • Middle East & Africa
    • GCC Countries
    • South Africa
    • Israel
    • Turkey
    • Rest of MEA

Frequently Asked Questions (FAQ) about the Antipsychotic Drugs market report